ResMed Inc Reports Strong First Quarter 2025 Financial Results Amidst Positive Growth and Strategic

RMD.N

2024-10-253mins

Content

ResMed Inc. Reports Strong First Quarter 2025 Financial Results Amidst Positive Growth and Strategic Initiatives

San Diego, October 24, 2024 – ResMed Inc. (NYSE: RMD, ASX: RMD) reported its financial results for the quarter ended September 30, 2024, showcasing robust growth and strategic execution across its operations.

Key Financial Metrics:

Metric	Current Quarter	Year-over-Year Change	Consensus Estimates
Revenue	$1.2 billion	+11%	$1.18 billion
Diluted Earnings Per Share (EPS)	$2.11	N/A	$2.04

The financial data reflects ResMed's strong market position, underscored by an 11% increase in revenue year-over-year, reaching $1.2 billion, surpassing the consensus estimate of $1.18 billion. The diluted earnings per share also exceeded expectations at $2.11 compared to the projected $2.04. These results indicate ResMed's capacity to outperform market anticipations, driven by substantial demand for its sleep devices and masks, contributing to a notable 11% revenue growth.

Revenue Segment Performance:

Segment	Revenue Growth	Notes
U.S., Canada, and Latin America	+11%	Excluding Residential Care Software
Europe, Asia, and other markets	+10%	Excluding Residential Care Software
Residential Care Software	+12%	Significant organic growth within the software portfolio

The company's segments showed strong performance, with notable expansion in all geographic areas and sectors, particularly in the Residential Care Software segment, which saw a substantial 12% increase in revenue.

Key Developments and Operational Highlights:

Celebrated 35 years of innovation and 25 years on the NYSE by ringing the Opening Bell®.
Held the 2024 Investor Day, announcing ResMed's 2030 strategy to accelerate growth and innovation.
Launched the AirTouch N30i, ResMed's first fabric mask, in the U.S., aimed at enhancing user comfort.
Introduced digital solutions integrated with AI for a personalized sleep health experience.

Company Commentary and Future Guidance:

Mick Farrell, Chairman and CEO of ResMed, noted, 'Our first-quarter fiscal year 2025 results reflect ongoing momentum and strong execution across all areas of our business. We delivered 11% year-over-year revenue growth, and our focus on operational excellence resulted in another quarter of year-over-year margin expansion and a 34% increase in operating profit.' The company remains committed to its ambitious 2030 strategy, aiming to expand its market reach and continue delivering innovative health solutions globally.

Dividends and Share Repurchase Program:

ResMed declared a quarterly cash dividend of $0.53 per share and executed a share repurchase of 222,000 shares for a total consideration of $50 million, which underscores its commitment to returning capital to shareholders.

Stock Price Movement:

Following the earnings release, ResMed's stock experienced a minor increase of approximately 0.70%, indicative of positive market reception to its robust first-quarter performance.

This record of financial strength and strategic foresight emphasizes ResMed's continued leadership in the sleep and respiratory care markets, as well as its adaptive approach in navigating evolving market demands.

For more in-depth analysis and insights, stay tuned with our platform to stay ahead of the market.